Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it ...

Gilead Sciences will pay more than $200 million after admitting to a multi-year illegal kickback scheme that pushed its HIV drugs through lavish perks for prescribers. New York Attorney General ...

Gilead Sciences (NASDAQ:GILD) has reached a $202M deal with a group of attorneys general in the U.S. to settle allegations ...

Massachusetts AG Campbell secures $1.6 million for the state's Medicaid in a settlement with Gilead over illegal kickbacks ...

The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

"Government health care dollars are precious and must be used without favor in order to achieve the highest possible health ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...

(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...

Gilead's Papao shares insights on the evolving role of public-private collaboration in healthcare, and how emerging tech is ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...

The country isn’t getting extra money from the Global Fund to Fight Aids, TB and Malaria; it has to use cash from a grant it ...